GSK-4112 is an experimental drug that was developed by
GlaxoSmithKline
GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the ten ...
as an agonist of
Rev-ErbAα. It is used for studying regulation of the
circadian rhythm
A circadian rhythm (), or circadian cycle, is a natural, internal process that regulates the sleep–wake cycle and repeats roughly every 24 hours. It can refer to any process that originates within an organism (i.e., Endogeny (biology), endogeno ...
and its influence on diverse processes such as
adipogenesis, regulation of
bone density, and
inflammation
Inflammation (from la, wikt:en:inflammatio#Latin, inflammatio) is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or Irritation, irritants, and is a protective response involving im ...
.
See also
*
SR8278
SR-8278 is an experimental drug that was developed as an antagonist of Rev-ErbAα. It has been used to demonstrate potential applications of Rev-ErbAα antagonists in the treatment of conditions such as Duchenne muscular dystrophy and Alzheimer' ...
*
SR9009
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repressor, repression of Regulation of gene expressi ...
*
SR9011
SR9011 is a research drug that was developed by Professor Thomas Burris of The Scripps Research Institute, Scripps as an agonist of Rev-ErbA alpha, Rev-ErbAα
with a half-maximum inhibitory concentration (IC50, IC50) = 790 nM for Rev-Erbα and IC ...
References
{{pharm-stub
Thiophenes
Tert-butyl compounds
Nitro compounds
Chlorobenzene derivatives
Amines
Esters